According to research from the University of Southern California, demand for semaglutide, a popular GLP-1 drug, surged by 442% between January 2021 and December 2023, partly due to a reduction in the stigma associated with obesity treatment.
This appetite suppression is a direct result of the medication's action on satiety centres in the brain and the delayed gastric emptying that creates prolonged feelings of fullness
The primary advantages of GLP-1RAs lie in glucose reduction, cardiorenal benefits, and amelioration of metabolic syndrome, all of which are substantiated by a plethora of evidence-based studies [1,2,3,4]
Long-term HGH use can reduce pituitary function, potentially creating dependence
1981 Nov-Dec;54(6):497-502
Baslington-Davies A, Howell H, Hogue TE, Mills DS